Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
ME Neganova, SG Klochkov, YR Aleksandrova… - Seminars in Cancer …, 2022 - Elsevier
Epigenetic changes associated with histone modifications play an important role in the
emergence and maintenance of the phenotype of various cancer types. In contrast to direct …
emergence and maintenance of the phenotype of various cancer types. In contrast to direct …
Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
Epigentic enzymes histone deacetylases (HDACs) catalyze the removal of acetyl groups
from the ε-N-acetylated lysine residues of various protein substrates including both histone …
from the ε-N-acetylated lysine residues of various protein substrates including both histone …
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …
targets which have been studied intensively in the past few decades. Although several drugs …
The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs
S Geurs, D Clarisse, K De Bosscher… - Journal of Medicinal …, 2023 - ACS Publications
Histone deacetylases (HDACs) are enzymes pursued as drug targets in various cancers and
several non-oncological conditions, such as inflammation and neurodegenerative disorders …
several non-oncological conditions, such as inflammation and neurodegenerative disorders …
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1, 3, 4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism
Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family mainly targeting
cytosolic nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 to …
cytosolic nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 to …
[HTML][HTML] Difluoromethyl-1, 3, 4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity
E Cellupica, G Caprini, P Cordella, C Cukier… - Journal of Biological …, 2023 - ASBMB
Histone deacetylase 6 (HDAC6) is an attractive drug development target because of its role
in the immune response, neuropathy, and cancer. Knockout mice develop normally and …
in the immune response, neuropathy, and cancer. Knockout mice develop normally and …
[HTML][HTML] Targeting epigenetic regulatory enzymes for cancer therapeutics: novel small-molecule epidrug development
Y Jin, T Liu, H Luo, Y Liu, D Liu - Frontiers in oncology, 2022 - frontiersin.org
Dysregulation of the epigenetic enzyme-mediated transcription of oncogenes or tumor
suppressor genes is closely associated with the occurrence, progression, and prognosis of …
suppressor genes is closely associated with the occurrence, progression, and prognosis of …
[HTML][HTML] Oxadiazole derivatives: Histone deacetylase inhibitors in anticancer therapy and drug discovery
Heterocycles are being playing an important role in cancer treatment for years. Currently, a
number of anticancer agents are available on market, but concerns such as less …
number of anticancer agents are available on market, but concerns such as less …
[HTML][HTML] Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases
J Li, M Yu, S Fu, D Liu, Y Tan - Frontiers in Pharmacology, 2022 - frontiersin.org
The deacetylation process regulated by histone deacetylases (HDACs) plays an important
role in human health and diseases. HDAC6 belongs to the Class IIb of HDACs family, which …
role in human health and diseases. HDAC6 belongs to the Class IIb of HDACs family, which …
[HTML][HTML] Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective
epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing …
epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing …